Literature DB >> 35876653

Longitudinal HIV care outcomes by gender identity in the United States.

Catherine R Lesko1, Jessie K Edwards2, David B Hanna3, Angel M Mayor4, Michael J Silverberg5, Michael Horberg6, Peter F Rebeiro7, Richard D Moore8, Ashleigh J Rich9, Kathleen A McGinnis10, Kate Buchacz11, Heidi M Crane12, Charles S Rabkin13, Keri N Althoff1, Tonia C Poteat9.   

Abstract

OBJECTIVE: Describe engagement in HIV care over time after initial engagement in HIV care, by gender identity.
DESIGN: Observational, clinical cohort study of people with HIV engaged in routine HIV care across the United States.
METHODS: We followed people with HIV who linked to and engaged in clinical care (attending ≥2 visits in 12 months) in cohorts in the North American Transgender Cohort Collaboration, 2000-2018. Within strata of gender identity, we estimated the 7-year (84-month) restricted mean time spent: lost-to-clinic (stratified by pre/postantiretroviral therapy (ART) initiation); in care prior to ART initiation; on ART but not virally suppressed; virally suppressed (≤200 copies/ml); or dead (pre/post-ART initiation).
RESULTS: Transgender women ( N  = 482/101 841) spent an average of 35.5 out of 84 months virally suppressed (this was 30.5 months for cisgender women and 34.4 months for cisgender men). After adjustment for age, race, ethnicity, history of injection drug use, cohort, and calendar year, transgender women were significantly less likely to die than cisgender people. Cisgender women spent more time in care not yet on ART, and less time on ART and virally suppressed, but were less likely to die compared with cisgender men. Other differences were not clinically meaningful.
CONCLUSIONS: In this sample, transgender women and cisgender people spent similar amounts of time in care and virally suppressed. Additional efforts to improve retention in care and viral suppression are needed for all people with HIV, regardless of gender identity.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35876653      PMCID: PMC9529804          DOI: 10.1097/QAD.0000000000003339

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.632


  38 in total

1.  Marginal structural models as a tool for standardization.

Authors:  Tosiya Sato; Yutaka Matsuyama
Journal:  Epidemiology       Date:  2003-11       Impact factor: 4.822

2.  Antiretroviral Treatment Interruptions Among Black and Latina Transgender Women Living with HIV: Characterizing Co-occurring, Multilevel Factors Using the Gender Affirmation Framework.

Authors:  Joseph G Rosen; Mannat Malik; Erin E Cooney; Andrea L Wirtz; Thespina Yamanis; Maren Lujan; Christopher Cannon; David Hardy; Tonia Poteat
Journal:  AIDS Behav       Date:  2019-09

3.  Fighting HIV/AIDS in Washington, D.C.

Authors:  Alan E Greenberg; Shannon L Hader; Henry Masur; A Toni Young; Jennifer Skillicorn; Carl W Dieffenbach
Journal:  Health Aff (Millwood)       Date:  2009 Nov-Dec       Impact factor: 6.301

4.  Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis.

Authors:  Tonia Poteat; David B Hanna; Peter F Rebeiro; Marina Klein; Michael J Silverberg; Joseph J Eron; Michael A Horberg; Mari M Kitahata; W C Mathews; Kristin Mattocks; Angel Mayor; Ashleigh J Rich; Sari Reisner; Jennifer Thorne; Richard D Moore; Yuezhou Jing; Keri N Althoff
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

Review 5.  The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection.

Authors:  Edward M Gardner; Margaret P McLees; John F Steiner; Carlos Del Rio; William J Burman
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

6.  Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy.

Authors:  Stephen R Cole; Bryan Lau; Joseph J Eron; M Alan Brookhart; Mari M Kitahata; Jeffrey N Martin; William C Mathews; Michael J Mugavero
Journal:  Am J Epidemiol       Date:  2014-06-24       Impact factor: 4.897

7.  Continuous Retention and Viral Suppression Provide Further Insights Into the HIV Care Continuum Compared to the Cross-sectional HIV Care Cascade.

Authors:  Jonathan Colasanti; Jane Kelly; Eugene Pennisi; Yi-Juan Hu; Christin Root; Denise Hughes; Carlos Del Rio; Wendy S Armstrong
Journal:  Clin Infect Dis       Date:  2015-11-12       Impact factor: 9.079

8.  U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.

Authors:  Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

9.  Service utilization and HIV outcomes among transgender women receiving Ryan White Part A services in New York City.

Authors:  Jacinthe A Thomas; Mary K Irvine; Qiang Xia; Graham A Harriman
Journal:  PLoS One       Date:  2021-07-01       Impact factor: 3.240

10.  HIV-related outcome disparities between transgender women living with HIV and cisgender people living with HIV served by the Health Resources and Services Administration's Ryan White HIV/AIDS Program: A retrospective study.

Authors:  Pamela W Klein; Demetrios Psihopaidas; Jessica Xavier; Stacy M Cohen
Journal:  PLoS Med       Date:  2020-05-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.